Insulin vs placebo
HbA1c (%) · adults with CFRD
1 finding from 1 review
- Drug treatments for managing cystic fibrosis‐related diabetes 2020 · Cochrane Headline outcomes onlyno estimate extracted1 study · 39 participantsVery low
Findings
What do systematic reviews say?
15 questions · 15 findings · 1 reviews · Cystic Fibrosis and Genetic Disorders · Headline outcomes only
No studies found 4 · 26.7%GRADE not reported 0 · 0%Very low 2 · 13.3%Low 6 · 40%Moderate 2 · 13.3%High 1 · 6.7%
Insulin vs placebo
FEV1 % predicted: absolute change from baseline · adults with CFRD
Summary of findings: insulin showed no clear difference in FEV1 % predicted: change from baseline compared with placebo (low certainty).
1 finding from 1 review
- Drug treatments for managing cystic fibrosis‐related diabetes 2020 · Cochrane Headline outcomes onlyMD 1.21 study · 39 participantsLow
Insulin vs placebo
FVC (% predicted) Change from baseline · adults with CFRD
Summary of findings: insulin showed no clear difference in FVC % predicted: change from baseline compared with placebo (low certainty).
1 finding from 1 review
- Drug treatments for managing cystic fibrosis‐related diabetes 2020 · Cochrane Headline outcomes onlyMD 0.61 study · 39 participantsLow
Insulin vs placebo
Change in BMI · adults with CFRD
Summary of findings: insulin showed no clear difference in BMI(kg/m²): change from baseline compared with placebo (low certainty).
1 finding from 1 review
- Drug treatments for managing cystic fibrosis‐related diabetes 2020 · Cochrane Headline outcomes onlyMD 0.411 study · 39 participantsLow
Insulin vs placebo
Hypoglycemia: number of episodes · adults with CFRD
Summary of findings: insulin showed no clear difference in hypoglycemia: number of episodes compared with placebo (low certainty).
1 finding from 1 review
- Drug treatments for managing cystic fibrosis‐related diabetes 2020 · Cochrane Headline outcomes onlyRR 9.23 [0.53, 159.14]1 study · 55 participantsLow
Summary of findings: NPH insulin vs insulin glargine
HbA1c (%) · adults with CFRD and fasting hyperglycemia
The review found no eligible studies for this question.
1 finding from 1 review
- Drug treatments for managing cystic fibrosis‐related diabetes 2020 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Summary of findings: NPH insulin vs insulin glargine
FEV1 % predicted · adults with CFRD and fasting hyperglycemia
The review found no eligible studies for this question.
1 finding from 1 review
- Drug treatments for managing cystic fibrosis‐related diabetes 2020 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Summary of findings: NPH insulin vs insulin glargine
FVC · adults with CFRD and fasting hyperglycemia
The review found no eligible studies for this question.
1 finding from 1 review
- Drug treatments for managing cystic fibrosis‐related diabetes 2020 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Summary of findings: NPH insulin vs insulin glargine
Body‐mass index (BMI) · adults with CFRD and fasting hyperglycemia
The review found no eligible studies for this question.
1 finding from 1 review
- Drug treatments for managing cystic fibrosis‐related diabetes 2020 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Summary of findings: NPH insulin vs insulin glargine
Hypoglycemia mean number of events per participant · adults with CFRD and fasting hyperglycemia
It is very uncertain whether summary of findings: NPH insulin changes hypoglycemia mean number of events per participant compared with glargine (very low certainty).
1 finding from 1 review
- Drug treatments for managing cystic fibrosis‐related diabetes 2020 · Cochrane Headline outcomes onlyno estimate extracted1 study · 19 participantsVery low
Summary of findings: repaglinide vs insulin
HbA1c (glycated haemoglobin), change · children over 12 and adults with CFRD
Summary of findings: repaglinide showed no clear difference in hbA1c (%) change from baseline compared with insulin (high certainty).
1 finding from 1 review
- Drug treatments for managing cystic fibrosis‐related diabetes 2020 · Cochrane Headline outcomes onlyMD 0.31 study · 67 participantsHigh
Summary of findings: repaglinide vs insulin
FEV1 (% predicted): mean change from baseline · children over 12 and adults with CFRD
Summary of findings: repaglinide showed no clear difference in FEV1 % predicted change from baseline compared with insulin (moderate certainty).
1 finding from 1 review
- Drug treatments for managing cystic fibrosis‐related diabetes 2020 · Cochrane Headline outcomes onlyno estimate extracted2 studies · 112 participantsModerate
Summary of findings: repaglinide vs insulin
FVC (% predicted) Change from baseline · children over 12 and adults with CFRD
Summary of findings: repaglinide showed no clear difference in FVC % predicted change from baseline compared with insulin (moderate certainty).
1 finding from 1 review
- Drug treatments for managing cystic fibrosis‐related diabetes 2020 · Cochrane Headline outcomes onlyno estimate extracted2 studies · 112 participantsModerate
Summary of findings: repaglinide vs insulin
Change in BMI · children over 12 and adults with CFRD
Summary of findings: repaglinide showed no clear difference in BMI (kg/m²) change from baseline compared with insulin (low certainty).
1 finding from 1 review
- Drug treatments for managing cystic fibrosis‐related diabetes 2020 · Cochrane Headline outcomes onlyMD 0.241 study · 45 participantsLow
Summary of findings: repaglinide vs insulin
Hypoglycemia: number of episodes · children over 12 and adults with CFRD
Summary of findings: repaglinide showed no clear difference in hypoglycemia number of episodes compared with insulin (low certainty).
1 finding from 1 review
- Drug treatments for managing cystic fibrosis‐related diabetes 2020 · Cochrane Headline outcomes onlyRR 1.38 [0.48, 4.01]2 studies · 56 participantsLow